

The Executive Office of Health & Human Services

Pharmacy and Therapeutics Committee Meeting Minutes



Tuesday, June 6, 2023

8:00 AM

EOHHS, Virks Building
3 West Road, Cranston, RI 02920

P & T Members Present:

Todd Brothers, PharmD
Nickolai Morin, PharmD
Tracey Taviera, PharmD
Matt Salisbury, MD
Rick Wagner, MD
Bill Quirk, RPh

Absent:

Greg Allen, MD
Dezeree Hodish, Assistant Director Financial and Contract Management (EOHHS)
Karen Mariano, RPh (Gainwell Technologies)

Others Present:

Ann Bennett, MHA (Gainwell Technologies)
Karen Murphy (Gainwell Technologies)
Jerry Fingerut, MD, Medical Director, (EOHHS)
Kathryn Novak, RPh (Magellan Medicaid Administration)

The meeting was called to order by the Chairperson once a quorum was in attendance –8:08 am. Chairperson Todd Brothers called the meeting to order and asked for introductions of the committee and those supporting the meeting.

Public testimony included the following speakers and topics.

Follow up information should be sent to karen.mariano@gainwelltechnologies.com for distribution to the committee.

P & T Speakers	Affiliation	Topic
Susan Tsang	Leo Pharma	Adbry
Annie Vong	Abbvie	Rinvoq
Nirav Patel	Novartis	Cosentyx
Name Unknown	Amgen	Otezla
Allen Nguyen	Gilead	Sunlenca and Epclusa

The April 2023, draft meeting minutes were approved.

Magellan Medicaid Administration (MMA) presented the following categories for therapeutic class reviews with discussion from the pharmacy and therapeutics committee. MMA reminded the audience that Medicaid covers all medications as long as the manufacturer has signed a contract with CMS even if it is not on the PDL. FFS RI Medicaid is secondary on many claims therefore the PDL compliance in some classes is not always the best due to other insurance paying most of the claim which allows it to bypass PDL rules. Also, informed the audience that this meeting and the Preferred Drug List is strictly for FFS RI Medicaid, not any of the Managed Care Organizations. MMA let the audience know that ADAP agreed with putting the categories of drugs on the PDL for the HIV population.

Therapeutic Categories		Comments & Discussion	Vote: Yes	Vote: No	Abstain	Motion
Anti-Infectives	Antibiotics, GI	Recommended change - move Firvanq to non-preferred	6	0	0	Pass
	Antibiotics, Vaginal	Recommended change – move Clindesse and Nuversa to non-preferred	6	0	0	Pass
	Antifungals, Oral	No recommended changes to the current preferred agents	6	0	0	Pass
	Antivirals, HSV	No recommended changes to the current preferred agents	6	0	0	Pass
	Antivirals, Influenza	No recommended changes to the current preferred agents	6	0	0	Pass
	Cephalosporins and Related Antibiotics	No recommended changes to the current preferred agents	6	0	0	Pass
	Fluoroquinolones	No recommended changes to the current preferred agents	6	0	0	Pass
	Hepatitis C Agents	Recommended change- move Vosevi to non-preferred	6	0	0	Pass
	HIV Agents	No recommended changes to the current preferred agents	6	0	0	Pass
	Macrolides-Ketolides	Recommended change- move E.E.S 200 suspension to non-preferred and erythromycin ethylsuccinate 200 suspension to preferred	6	0	0	Pass
	Tetracyclines, Oral	Recommended change – move doxycycline monohydrate tablet to preferred	6	0	0	Pass
Dermatological	Acne Agents, Topical	Recommended change – move tretinoin cream to preferred and Retin-A cream to non-preferred	6	0	0	Pass
	Antibiotics, Topical	No recommended changes to the current preferred agents	6	0	0	Pass
	Antifungal, Topical	No recommended changes to the	6	0	0	Pass

		current preferred agents				
	Antipsoriatics, Topical	No recommended changes to the current preferred agents	6	0	0	Pass
	Antiviral Agents, Topical	No recommended changes to the current preferred agents	6	0	0	Pass
	Immunomodulators, Atopic Dermatitis	No recommended changes to the current preferred Agents	6	0	0	Pass
	Immunomodulators, Topical	No recommended changes to the current preferred agents	6	0	0	Pass
	Rosacea Agents	Recommended change – move metronidazole cream and gel to preferred	6	0	0	Pass
	Steroids Topical	No recommended changes to the current preferred agents	6	0	0	Pass
Immunologic	Cytokine and CAM Antagonists	Recommended change – move Otezla to preferred – there was a discussion about biosimilars – MMA explained that the new rebate eligible biosimilars in this category will be included in the mid-year solicitation this summer. MMA will consider clinical information and financial information when making PDL status recommendations to the state regarding products in the class.	6	0	0	Pass
	Methotrexate Agents	No recommended changes to the current preferred agents	6	0	0	Pass
Respiratory	Anti-allergens, oral	No recommended changes to the current preferred agents	6	0	0	Pass
	Antibiotics, Inhaled	No recommended changes to the current preferred agents	6	0	0	Pass
	Antihistamines, Minimally Sedating	No recommended changes to the	6	0	0	Pass

		current preferred agents				
	Bronchodilators, Beta-Agonists	Recommended change – move Xopenex HFA to preferred	6	0	0	Pass
	COPD Agents	No recommended changes to the current preferred agents	6	0	0	Pass
	Epinephrine, Self-Injected	No recommended changes to the current preferred agents	6	0	0	Pass
	Glucocorticoids, Inhaled	No recommended changes to the current preferred agents	6	0	0	Pass
	Glucocorticoids, Oral	No recommended changes to the current preferred agents	6	0	0	Pass
	Immunomodulators, Asthma	No recommended changes to the current preferred agents	6	0	0	Pass
	Intranasal Rhinitis Agents	Recommended change – move Dymista to preferred	6	0	0	Pass
	Leukotriene Modifiers	No recommended changes to the current preferred agents	6	0	0	Pass

Next Meeting

Tuesday, September 12, 2023

Meeting schedule for the year:

September 12, 2023

December 12, 2023

Adjournment

The meeting adjourned at 9:28AM